Sofosbuvir Activates EGFR-Dependent Pathways in Hepatoma Cells with Implications for Liver-Related Pathological Processes
Abstract
:1. Introduction
2. Materials and Methods
2.1. Cell Culture and Compounds
2.2. Cell Cycle Analysis by DNA Staining
2.3. Measurement of Apoptosis, Proliferation, and Cytotoxicity
2.4. Immunoblot Analysis
2.5. Serine/Threonine Kinase Profiling
2.6. Statistics
3. Results
3.1. Cell Cycle Distribution after DAA Treatment in Hepatoma Cell Lines
3.2. Sofosbuvir Induces Pro-Survival Changes in Hepatoma Cells
3.3. SOF Induces Activation of EGFR in Hepatoma Cells
3.4. Activity-Based Kinases Profiling in Hepatoma Cells Reveals Pathways Activated by SOF Treatment
3.5. Regulation and Nuclear Translocation of SOF-Activated EGFR
3.6. Role of Other Nucleoside Analogues in EGFR Activation
4. Discussion
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- World Health Organization. Global Hepatitis Report 2017; World Health Organization: Geneva, Switzerland, 2017. [Google Scholar]
- Ferenci, P.; Fried, M.; Labrecque, D.; Bruix, J.; Sherman, M.; Omata, M.; Heathcote, J.; Piratsivuth, T.; Kew, M.; Otegbayo, J.A.; et al. Hepatocellular Carcinoma (HCC). J. Clin. Gastroenterol. 2010, 44, 239–245. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Poordad, F.; Hezode, C.; Trinh, R.; Kowdley, K.V.; Zeuzem, S.; Agarwal, K.; Shiffman, M.L.; Wedemeyer, H.; Berg, T.; Yoshida, E.M.; et al. ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis. N. Engl. J. Med. 2014, 370, 1973–1982. [Google Scholar] [CrossRef] [Green Version]
- Poordad, F.; Schiff, E.R.; Vierling, J.M.; Landis, C.; Fontana, R.J.; Yang, R.; McPhee, F.; Hughes, E.A.; Noviello, S.; Swenson, E.S. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016, 63, 1493–1505. [Google Scholar] [CrossRef] [PubMed]
- Charlton, M.; Everson, G.T.; Flamm, S.L.; Kumar, P.; Landis, C.; Brown, R.S.; Fried, M.W.; Terrault, N.A.; O’Leary, J.G.; Vargas, H.E.; et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology 2015, 149, 649–659. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Conti, F.; Buonfiglioli, F.; Scuteri, A.; Crespi, C.; Bolondi, L.; Caraceni, P.; Foschi, F.G.; Lenzi, M.; Mazzella, G.; Verucchi, G.; et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J. Hepatol. 2016, 65, 727–733. [Google Scholar] [CrossRef] [PubMed]
- Reig, M.; Mariño, Z.; Perelló, C.; Iñarrairaegui, M.; Ribeiro, A.; Lens, S.; Díaz, A.; Vilana, R.; Darnell, A.; Varela, M.; et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J. Hepatol. 2016, 65, 719–726. [Google Scholar] [CrossRef] [Green Version]
- Renzulli, M.; Buonfiglioli, F.; Conti, F.; Brocchi, S.; Serio, I.; Foschi, F.G.; Caraceni, P.; Mazzella, G.; Verucchi, G.; Golfieri, R.; et al. Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis. Eur. Radiol. 2017, 28, 506–513. [Google Scholar] [CrossRef]
- Calleja-Panero, J.L.; Crespo, J.; Rincon, D.; Ruiz-Antorán, B.; Fernández, I.; Perelló, C.; Gea, F.; Lens, S.; García-Samaniego, J.; Sacristán, B.; et al. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. J. Hepatol. 2017, 66, 1138–1148. [Google Scholar] [CrossRef]
- Ikeda, K.; Kawamura, Y.; Kobayashi, M.; Kominami, Y.; Fujiyama, S.; Sezaki, H.; Hosaka, T.; Akuta, N.; Saitoh, S.; Suzuki, F.; et al. Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma. Dig. Dis. Sci. 2017, 62, 2932–2942. [Google Scholar] [CrossRef]
- Yang, J.D.; Aqel, B.A.; Pungpapong, S.; Gores, G.J.; Roberts, L.R.; Leise, M.D. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J. Hepatol. 2016, 65, 859–860. [Google Scholar] [CrossRef] [Green Version]
- Ravi, S.; Axley, P.; Jones, D.; Kodali, S.; Simpson, H.; McGuire, B.M.; Singal, A.K. Unusually High Rates of Hepatocellular Carcinoma After Treatment With Direct-Acting Antiviral Therapy for Hepatitis C Related Cirrhosis. Gastroenterology 2017, 152, 911–912. [Google Scholar] [CrossRef] [Green Version]
- Nahon, P.; Layese, R.; Bourcier, V.; Cagnot, C.; Marcellin, P.; Guyader, D.; Pol, S.; Larrey, D.; De Lédinghen, V.; Ouzan, D.; et al. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. Gastroenterology 2018, 155, 1436–1450.e6. [Google Scholar] [CrossRef] [Green Version]
- Serti, E.; Chepa-Lotrea, X.; Kim, Y.J.; Keane, M.; Fryzek, N.; Liang, T.J.; Ghany, M.; Rehermann, B. Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. Gastroenterology 2015, 149, 190–200.e2. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Meissner, E.G.; Wu, D.; Osinusi, A.; Bon, D.; Virtaneva, K.; Sturdevant, D.; Porcella, S.; Wang, H.; Herrmann, E.; McHutchison, J.; et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J. Clin. Investig. 2014, 124, 3352–3363. [Google Scholar] [CrossRef] [Green Version]
- Debes, J.D.; Van Tilborg, M.; Groothuismink, Z.M.; Hansen, B.E.; Wiesch, J.S.Z.; Von Felden, J.; De Knegt, R.J.; Boonstra, A. Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-Acting Antivirals. Gastroenterology 2018, 154, 515–517.e3. [Google Scholar] [CrossRef]
- Villani, R.; Facciorusso, A.; Bellanti, F.; Tamborra, R.; Piscazzi, A.; Landriscina, M.; Vendemiale, G.; Serviddio, G. DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment. PLoS ONE 2016, 11. [Google Scholar] [CrossRef] [Green Version]
- Faillaci, F.; Marzi, L.; Critelli, R.; Milosa, F.; Schepis, F.; Turola, E.; Andreani, S.; Vandelli, G.; Bernabucci, V.; Lei, B.; et al. Liver Angiopoietin-2 Is a Key Predictor of D e N ovo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals. Hepatology 2018, 68, 1010–1024. [Google Scholar] [CrossRef] [Green Version]
- Vondran, F.W.; Katenz, E.; Schwartlander, R.; Morgul, M.H.; Raschzok, N.; Gong, X.; Cheng, X.; Kehr, D.; Sauer, I.M. Isolation of Primary Human Hepatocytes After Partial Hepatectomy: Criteria for Identification of the Most Promising Liver Specimen. Artif. Organs 2008, 32, 205–213. [Google Scholar] [CrossRef]
- Werner, M.; Driftmann, S.; Kleinehr, K.; Kaiser, G.M.; Mathé, Z.; Treckmann, J.W.; Paul, A.; Skibbe, K.; Timm, J.; Canbay, A.; et al. All-In-One: Advanced preparation of Human Parenchymal and Non-Parenchymal Liver Cells. PLoS ONE 2015, 10, e0138655. [Google Scholar] [CrossRef] [Green Version]
- Kirby, B.J.; Symonds, W.T.; Kearney, B.P.; Mathias, A.A. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir. Clin. Pharmacokinet. 2015, 54, 677–690. [Google Scholar] [CrossRef]
- Gandhi, Y.; Eley, T.; Fura, A.; Li, W.; Bertz, R.J.; Garimella, T. Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics. Clin. Pharmacokinet. 2018, 57, 911–928. [Google Scholar] [CrossRef]
- Ouwerkerk-Mahadevan, S.; Beumont-Mauviel, M.; Mortier, S.; Peeters, M.; Verloes, R.; Truyers, C.; Mannens, G.; Wynant, I.; Simion, A. Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal Impairment. Drugs R&D 2015, 15, 261–270. [Google Scholar] [CrossRef] [Green Version]
- Mumtaz, N.; Jimmerson, L.C.; Bushman, L.R.; Kiser, J.J.; Aron, G.; Reusken, C.B.; Koopmans, M.P.; Van Kampen, J.J. Cell-line dependent antiviral activity of sofosbuvir against Zika virus. Antivir. Res. 2017, 146, 161–163. [Google Scholar] [CrossRef]
- Feng, J.Y. Addressing the selectivity and toxicity of antiviral nucleosides. Antivir. Chem. Chemother. 2018, 26. [Google Scholar] [CrossRef]
- Roos, W.; Thomas, A.; Kaina, B. DNA damage and the balance between survival and death in cancer biology. Nat. Rev. Cancer 2015, 16, 20–33. [Google Scholar] [CrossRef]
- Resnitzky, D.; Gossen, M.; Bujard, H.; Reed, S.I. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol. Cell. Biol. 1994, 14, 1669–1679. [Google Scholar] [CrossRef]
- Musa, J.; Aynaud, M.M.; Mirabeau, O.; Delattre, O.; Grünewald, T.G.P. MYBL2 (B-Myb): A central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis. Cell Death Dis. 2017, 8, e2895. [Google Scholar] [CrossRef]
- Hanada, N.; Lo, H.W.; Day, C.P.; Pan, Y.; Nakajima, Y.; Hung, M.C. Co-regulation of B-Myb expression by E2F1 and EGF receptor. Mol. Carcinog. 2005, 45, 10–17. [Google Scholar] [CrossRef]
- Lin, S.Y.; Makino, K.; Xia, W.; Matin, A.; Wen, Y.; Kwong, K.Y.; Bourguignon, L.; Hung, M.C. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol. 2001, 3, 802–808. [Google Scholar] [CrossRef]
- Olsen, J.V.; Blagoev, B.; Gnad, F.; Macek, B.; Kumar, C.; Mortensen, P.; Mann, M. Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks. Cell 2006, 127, 635–648. [Google Scholar] [CrossRef] [Green Version]
- Tomas, A.; Jones, S.; Vaughan, S.O.; Hochhauser, D.; Futter, C. Stress-specific p38 MAPK activation is sufficient to drive EGFR endocytosis but not its nuclear translocation. J. Cell Sci. 2017, 130, 2481–2490. [Google Scholar] [CrossRef] [Green Version]
- Zwang, Y.; Yarden, Y. p38 MAP kinase mediates stress-induced internalization of EGFR: Implications for cancer chemotherapy. EMBO J. 2006, 25, 4195–4206. [Google Scholar] [CrossRef] [Green Version]
- Marzi, L.; Combes, E.; Vié, N.; Ayrolles-Torro, A.; Tosi, D.; Desigaud, D.; Perez-Gracia, E.; Larbouret, C.; Montagut, C.; Iglesias, M.; et al. FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer. Br. J. Cancer 2016, 115, 1223–1233. [Google Scholar] [CrossRef] [Green Version]
- Wang, Y.N.; Hung, M.C. Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family. Cell Biosci. 2012, 2, 13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gong, X.; Ming, X.; Deng, P.; Jiang, Y. Mechanisms regulating the nuclear translocation of p38 MAP kinase. J. Cell. Biochem. 2010, 110, 1420–1429. [Google Scholar] [CrossRef] [PubMed]
- Kozbial, K.; Moser, S.; Schwarzer, R.; Laferl, H.; Al-Zoairy, R.; Stauber, R.; Stättermayer, A.F.; Beinhardt, S.; Graziadei, I.; Freissmuth, C.; et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J. Hepatol. 2016, 65, 856–858. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sampath, D.; Rao, V.A.; Plunkett, W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003, 22, 9063–9074. [Google Scholar] [CrossRef] [Green Version]
- Frau, M.; Ladu, S.; Calvisi, D.F.; Simile, M.M.; Bonelli, P.; Daino, L.M.E.; Tomasi, M.L.; Seddaiu, M.A.; Feo, F.; Pascale, R.M. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype. J. Hepatol. 2011, 55, 111–119. [Google Scholar] [CrossRef]
- Biliran, H.; Wang, Y.; Banerjee, S.; Xu, H.; Heng, H.; Thakur, A.; Bollig-Fischer, A.; Sarkar, F.H.; Liao, J.D. Overexpression of Cyclin D1 Promotes Tumor Cell Growth and Confers Resistance to Cisplatin-Mediated Apoptosis in an Elastase-myc Transgene-Expressing Pancreatic Tumor Cell Line. Clin. Cancer Res. 2005, 11, 6075–6086. [Google Scholar] [CrossRef] [Green Version]
- Shimura, T.; Noma, N.; Oikawa, T.; Ochiai, Y.; Kakuda, S.; Kuwahara, Y.; Takai, Y.; Takahashi, A.; Fukumoto, M. Activation of the AKT/cyclin D1/Cdk4 survival signaling pathway in radioresistant cancer stem cells. Oncogenesis 2012, 1, e12. [Google Scholar] [CrossRef] [Green Version]
- Calvisi, D.F.; Simile, M.M.; Ladu, S.; Frau, M.; Tomasi, M.L.; Demartis, M.I.; Daino, L.M.E.; Seddaiu, M.A.; Brozzetti, S.; Feo, F.; et al. Activation of v?Myb avian myeloblastosis viral oncogene homolog?like2 (MYBL2)?LIN9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant p53 †. Hepatology 2011, 53, 1226–1236. [Google Scholar] [CrossRef]
- Feng, J.Y.; Xu, Y.; Barauskas, O.; Perry, J.K.; Ahmadyar, S.; Stepan, G.; Yu, H.; Babusis, D.; Park, Y.; McCutcheon, K.; et al. Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus. Antimicrob. Agents Chemother. 2016, 60, 806–817. [Google Scholar] [CrossRef] [Green Version]
- Dittmann, K.; Mayer, C.; Kehlbach, R.; Rodemann, H.P. Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. Mol. Cancer 2008, 7, 69. [Google Scholar] [CrossRef] [Green Version]
- Mialon, A.; Sankinen, M.; Söderstroöm, H.; Junttila, T.T.; Holmstroöm, T.; Koivusalo, R.; Papageorgiou, A.C.; Johnson, R.S.; Hietanen, S.; Elenius, K.; et al. DNA Topoisomerase I Is a Cofactor for c-Jun in the Regulation of Epidermal Growth Factor Receptor Expression and Cancer Cell Proliferation. Mol. Cell. Boil. 2005, 25, 5040–5051. [Google Scholar] [CrossRef] [Green Version]
- Johnson, A.; Murphy, B.A.; Matelis, C.M.; Rubinstein, Y.; Piebenga, E.C.; Akers, L.M.; Neta, G.; Vinson, C.; Birrer, M. Activator protein-1 mediates induced but not basal epidermal growth factor receptor gene expression. Mol. Med. 2000, 6, 17–27. [Google Scholar] [CrossRef]
- Brunet, A.; Bonni, A.; Zigmond, M.J.; Lin, M.Z.; Juo, P.; Hu, L.S.; Anderson, M.J.; Arden, K.C.; Blenis, J.; Greenberg, M.E. Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor. Cell 1999, 96, 857–868. [Google Scholar] [CrossRef] [Green Version]
- Barlow, C.; Kitiphongspattana, K.; Siddiqui, N.; Roe, M.W.; Mossman, B.T.; Lounsbury, K.M. Protein kinase A-mediated CREB phosphorylation is an oxidant-induced survival pathway in alveolar type II cells. Apoptosis 2008, 13, 681–692. [Google Scholar] [CrossRef] [Green Version]
- Wu, D.; Zhau, H.E.; Huang, W.C.; Iqbal, S.; Habib, F.K.; Sartor, O.; Cvitanovic, L.; Marshall, F.F.; Xu, Z.; Chung, L.W.K. cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: Implication in human prostate cancer bone metastasis. Oncogene 2007, 26, 5070–5077. [Google Scholar] [CrossRef] [Green Version]
- Wee, P.; Wang, Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers 2017, 9, 52. [Google Scholar] [CrossRef] [Green Version]
- Tanaka, T.; Ozawa, T.; Oga, E.; Muraguchi, A.; Sakurai, H. Cisplatin-induced non-canonical endocytosis of EGFR via p38 phosphorylation of the C-terminal region containing Ser-1015 in non-small cell lung cancer cells. Oncol. Lett. 2018, 15, 9251–9256. [Google Scholar] [CrossRef] [Green Version]
- Brüning, A.; Burger, P.; Gingelmaier, A.; Mylonas, I. The HIV reverse transcriptase inhibitor tenofovir induces cell cycle arrest in human cancer cells. Investig. New Drugs 2011, 30, 1389–1395. [Google Scholar] [CrossRef] [PubMed]
- Fang, J.L.; Beland, F.A. Long-Term Exposure to Zidovudine Delays Cell Cycle Progression, Induces Apoptosis, and Decreases Telomerase Activity in Human Hepatocytes. Toxicol. Sci. 2009, 111, 120–130. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Olivero, O.A.; Tejera, A.M.; Fernandez, J.J.; Taylor, B.J.; Das, S.; Divi, R.L.; Poirier, M.C. Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis 2005, 20, 139–146. [Google Scholar] [CrossRef]
- Olivero, O.A.; Beland, F.A.; Fullerton, N.F.; Poirier, M.C. Vaginal Epithelial DNA Damageand Expressionof PreneoplasticMarkers. Cancer Res. 1994, 54, 6235–6242. [Google Scholar]
- Hoshida, Y.; Fuchs, B.C.; Bardeesy, N.; Baumert, T.F.; Chung, R.T. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J. Hepatol. 2014, 61, S79–S90. [Google Scholar] [CrossRef] [Green Version]
- Fuchs, B.C.; Hoshida, Y.; Fujii, T.; Wei, L.; Yamada, S.; Lauwers, G.Y.; McGinn, C.M.; Deperalta, D.K.; Chen, X.; Kuroda, T.; et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology 2014, 59, 1577–1590. [Google Scholar] [CrossRef] [Green Version]
- Hoshida, Y.; Villanueva, A.; SanGiovanni, A.; Sole, M.; Hur, C.; Andersson, K.L.; Chung, R.T.; Gould, J.; Kojima, K.; Gupta, S.; et al. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 2013, 144, 1024–1030. [Google Scholar] [CrossRef] [Green Version]
- Ito, Y.; Takeda, T.; Sakon, M.; Tsujimoto, M.; Higashiyama, S.; Noda, K.; Miyoshi, E.; Monden, M.; Matsuura, N. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br. J. Cancer 2001, 84, 1377–1383. [Google Scholar] [CrossRef] [Green Version]
- Lupberger, J.; Zeisel, M.B.; Xiao, F.; Thumann, C.; Fofana, I.; Zona, L.; Davis, C.; Mee, C.; Turek, M.; Gorke, S.; et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat. Med. 2011, 17, 589–595. [Google Scholar] [CrossRef] [Green Version]
- Brenndörfer, E.D.; Karthe, J.; Frelin, L.; Cebula, P.; Erhardt, A.; Schulte am Esch, J.; Hengel, H.; Bartenschlager, R.; Sällberg, M.; Häussinger, D.; et al. Nonstructural 3/4A protease of hepatitis C virus activates epithelial growth factor-induced signal transduction by cleavage of the T-cell protein tyrosine phosphatase. Hepatology 2009, 49, 1810–1820. [Google Scholar] [CrossRef] [PubMed]
- Diao, J.; Pantua, H.; Ngu, H.; Komuves, L.; Diehl, L.; Schaefer, G.; Kapadia, S.B. Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry. J. Virol. 2012, 86, 10935–10949. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hamdane, N.; Jühling, F.; Crouchet, E.; El Saghire, H.; Thumann, C.; Oudot, M.A.; Bandiera, S.; Saviano, A.; Ponsolles, C.; Suarez, A.A.R.; et al. HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response. Gastroenterology 2019, 156, 2313–2329.e7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Perez, S.; Kaspi, A.; Domovitz, T.; Davidovich, A.; Lavi-Itzkovitz, A.; Meirson, T.; Holmes, J.A.; Dai, C.Y.; Huang, C.F.; Chung, R.T.; et al. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals. PLoS Genet. 2019, 15, e1008181. [Google Scholar] [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bojkova, D.; Westhaus, S.; Costa, R.; Timmer, L.; Funkenberg, N.; Korencak, M.; Streeck, H.; Vondran, F.; Broering, R.; Heinrichs, S.; et al. Sofosbuvir Activates EGFR-Dependent Pathways in Hepatoma Cells with Implications for Liver-Related Pathological Processes. Cells 2020, 9, 1003. https://doi.org/10.3390/cells9041003
Bojkova D, Westhaus S, Costa R, Timmer L, Funkenberg N, Korencak M, Streeck H, Vondran F, Broering R, Heinrichs S, et al. Sofosbuvir Activates EGFR-Dependent Pathways in Hepatoma Cells with Implications for Liver-Related Pathological Processes. Cells. 2020; 9(4):1003. https://doi.org/10.3390/cells9041003
Chicago/Turabian StyleBojkova, Denisa, Sandra Westhaus, Rui Costa, Lejla Timmer, Nora Funkenberg, Marek Korencak, Hendrik Streeck, Florian Vondran, Ruth Broering, Stefan Heinrichs, and et al. 2020. "Sofosbuvir Activates EGFR-Dependent Pathways in Hepatoma Cells with Implications for Liver-Related Pathological Processes" Cells 9, no. 4: 1003. https://doi.org/10.3390/cells9041003